IOVA
NASDAQ · Biotechnology
Iovance Biotherapeutics Inc
$3.89
+0.27 (+7.46%)
Financial Highlights (FY 2026)
Revenue
226.27M
Net Income
-513,269,012
Gross Margin
24.4%
Profit Margin
-226.8%
Rev Growth
—
D/E Ratio
0.00
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 24.4% | 62.6% | 62.6% | 62.6% |
| Operating Margin | -240.9% | 8.6% | 9.3% | 8.6% |
| Profit Margin | -226.8% | 7.0% | 5.4% | 7.7% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 226.27M | 337.04M | 333.93M | 362.22M |
| Gross Profit | 55.28M | 210.86M | 208.91M | 226.61M |
| Operating Income | -545,133,825 | 29.04M | 30.95M | 31.15M |
| Net Income | -513,269,012 | 23.64M | 18.09M | 27.70M |
| Gross Margin | 24.4% | 62.6% | 62.6% | 62.6% |
| Operating Margin | -240.9% | 8.6% | 9.3% | 8.6% |
| Profit Margin | -226.8% | 7.0% | 5.4% | 7.7% |
| Rev Growth | — | +17.4% | +6.9% | +2.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 790.8K | 109.76M | 100.41M | 133.92M |
| Total Equity | 564.89M | 546.43M | 592.21M | 571.74M |
| D/E Ratio | 0.00 | 0.20 | 0.17 | 0.23 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -528,620,309 | 42.24M | 40.52M | 39.62M |
| Free Cash Flow | — | 21.56M | 19.96M | 24.65M |